MA28080A1 - Derives de tropane a substituant imidazopyridine ayant une activite antagoniste des recepteurs ccr5, pour le traitement de l'infection par le vih et de l'inflammation - Google Patents
Derives de tropane a substituant imidazopyridine ayant une activite antagoniste des recepteurs ccr5, pour le traitement de l'infection par le vih et de l'inflammationInfo
- Publication number
- MA28080A1 MA28080A1 MA28906A MA28906A MA28080A1 MA 28080 A1 MA28080 A1 MA 28080A1 MA 28906 A MA28906 A MA 28906A MA 28906 A MA28906 A MA 28906A MA 28080 A1 MA28080 A1 MA 28080A1
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitors
- treatment
- combination
- additional therapeutic
- imidazopyridine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- AIDS & HIV (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
Abstract
20. Association d'un composé de formule (I) telle que définie dans l'une quelconque des revendications 1 à 7, ou d'un sel ou produit de solvatation pharmaceutiquement acceptable de ce composé, avec un ou plusieurs agents thérapeutiques supplémentaires. 21. Association suivant la revendication 20, dans laquelle le ou les agents thérapeutiques supplémentaires sont choisis parmi ceux utiles dans le traitement de maladies à médiation par, ou associées à, la modulation des récepteurs CCR5. 22. Association suivant la revendication 21, dans laquelle; le ou les agents thérapeutiques supplémentaires sont choisis parmi ceux utiles dans le traitement contre le VIH. 23. Association suivant l'une quelconque des revendications 20 à 22, dans laquelle le ou les agents thérapeutiques supplémentaires sont choisis entre des inhibiteurs de protéases du VIH, des inhibiteurs de transcriptase inverse et non nucléosidiques, des inhibiteurs de transcriptase inverse nucléosidiques/nucléotidiques, d'autres antagonistes de CCR5, des agents qui inhibent l'interaction de gp120 avec CD4, d'autres agents qui inhibent l'entrée du VIH dans la cellule cible, des inhibiteurs d'intégrase et des inhibiteurs de RNaseH. DEPOSANT Société dite: PFIZER INC. REVENDICATION DE PRIORITES GB 3 Octobre 2003 0323236.0 GB 27 Octobre 2003 0325020.6 GB 19 Août 2004 0418566.6 Voir en annexe le titre de l'invention et le texte de l'abrégé
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0323236.0A GB0323236D0 (en) | 2003-10-03 | 2003-10-03 | Chemical compounds |
| GB0325020A GB0325020D0 (en) | 2003-10-27 | 2003-10-27 | Chemical compounds |
| GB0418566A GB0418566D0 (en) | 2004-08-19 | 2004-08-19 | Tropane derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA28080A1 true MA28080A1 (fr) | 2006-08-01 |
Family
ID=34426592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA28906A MA28080A1 (fr) | 2003-10-03 | 2006-04-03 | Derives de tropane a substituant imidazopyridine ayant une activite antagoniste des recepteurs ccr5, pour le traitement de l'infection par le vih et de l'inflammation |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US7309790B2 (fr) |
| EP (1) | EP1682545B1 (fr) |
| JP (1) | JP4874107B2 (fr) |
| KR (1) | KR100777885B1 (fr) |
| AP (1) | AP2174A (fr) |
| AR (1) | AR045856A1 (fr) |
| AT (1) | ATE380813T1 (fr) |
| AU (1) | AU2004278158B2 (fr) |
| BR (1) | BRPI0414862A (fr) |
| CA (1) | CA2540834C (fr) |
| CY (1) | CY1107281T1 (fr) |
| DE (1) | DE602004010708T2 (fr) |
| DK (1) | DK1682545T3 (fr) |
| EA (1) | EA009941B1 (fr) |
| EC (1) | ECSP066475A (fr) |
| ES (1) | ES2295924T3 (fr) |
| GE (1) | GEP20084417B (fr) |
| HN (1) | HN2004000383A (fr) |
| HR (1) | HRP20080052T3 (fr) |
| IL (1) | IL174208A0 (fr) |
| MA (1) | MA28080A1 (fr) |
| MX (1) | MXPA06003749A (fr) |
| MY (1) | MY137609A (fr) |
| NO (1) | NO20061978L (fr) |
| NZ (1) | NZ545837A (fr) |
| OA (1) | OA13266A (fr) |
| PA (1) | PA8614301A1 (fr) |
| PE (1) | PE20050961A1 (fr) |
| PL (1) | PL1682545T3 (fr) |
| PT (1) | PT1682545E (fr) |
| RS (1) | RS20060198A (fr) |
| SI (1) | SI1682545T1 (fr) |
| TW (1) | TWI280244B (fr) |
| UY (1) | UY28546A1 (fr) |
| WO (1) | WO2005033107A1 (fr) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20030762A1 (es) | 2001-12-18 | 2003-09-05 | Schering Corp | Compuestos heterociclicos como antagonistas nk1 |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| KR101201603B1 (ko) | 2003-07-30 | 2012-11-14 | 리겔 파마슈티칼스, 인크. | 자가면역 질환의 치료 또는 예방에 사용하기 위한2,4-피리미딘디아민 화합물 |
| US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| EP1904457B1 (fr) | 2005-06-08 | 2017-09-06 | Rigel Pharmaceuticals, Inc. | Compositions et procedes d'inhibition de la voie jak |
| JP2009528295A (ja) | 2006-02-24 | 2009-08-06 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｊａｋ経路の阻害のための組成物および方法 |
| AR060303A1 (es) | 2006-04-05 | 2008-06-04 | Schering Corp | Formulaciones farmaceuticas sales de 8- [1- (3,5 -bis- (trifluorometil) fenil) -etoximetil] -8-fenil-1,7 -diaza-espiro [4.5] decan -2- ona y metodos de tratamiento utilizando las mismas |
| WO2008030853A2 (fr) * | 2006-09-06 | 2008-03-13 | Incyte Corporation | Thérapie de combinaison contre l'infection par le virus de l'immunodéficience humaine |
| JP5161233B2 (ja) | 2006-10-19 | 2013-03-13 | ライジェル ファーマシューティカルズ， インコーポレイテッド | 自己免疫疾患の処置のためのｊａｋキナーゼの阻害剤としての２，４−ピリミジンアミン誘導体 |
| WO2008085302A1 (fr) * | 2006-12-20 | 2008-07-17 | Merck & Co., Inc. | Analogues de l'imidazopyridine en tant que modulateurs du récepteur de cb2, utilisables pour le traitement de la douleur et des maladies respiratoires et non respiratoires |
| AR065802A1 (es) * | 2007-03-22 | 2009-07-01 | Schering Corp | Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas |
| ATE459622T1 (de) * | 2007-10-25 | 2010-03-15 | Exelixis Inc | Tropanverbindungen |
| PL2265607T3 (pl) | 2008-02-15 | 2017-07-31 | Rigel Pharmaceuticals, Inc. | Związki pirymidyno-2-aminowe i ich zastosowanie jako inhibitory kinaz JAK |
| US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| BRPI0910921B1 (pt) | 2008-04-16 | 2022-06-21 | Portola Pharmaceuticals, Inc | Inibidores de proteína syk quinase, composição farmacêutica, kit e usos dos referidos inibidores |
| CA2723185A1 (fr) | 2008-04-22 | 2009-10-29 | Portola Pharmaceuticals, Inc. | Inhibiteurs de proteines kinases |
| SG176464A1 (en) | 2008-05-09 | 2011-12-29 | Agency Science Tech & Res | Diagnosis and treatment of kawasaki disease |
| CN102573475B (zh) | 2009-08-14 | 2016-01-20 | 欧科生医股份有限公司 | 神经激肽-1拮抗剂的静脉内制剂 |
| EP2552429A1 (fr) | 2010-04-02 | 2013-02-06 | Phivco-1 LLC | Traitement d'association comprenant un antagoniste du récepteur ccr5, un inhibiteur de la protéase du vih-1 et un accélérateur pharmacocinétique |
| TW201300360A (zh) | 2010-11-01 | 2013-01-01 | Portola Pharm Inc | 做為ｊａｋ激酶調節劑之菸鹼醯胺 |
| US20140271680A1 (en) | 2011-08-12 | 2014-09-18 | Universite Paris-Est Creteil Val De Marne | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
| US9359308B2 (en) | 2011-11-23 | 2016-06-07 | Portola Pharmaceuticals, Inc. | Pyrazine kinase inhibitors |
| EP2903970A4 (fr) | 2012-10-08 | 2016-11-30 | Portola Pharm Inc | Inhibiteurs substitués de pyrimidinyl kinase |
| PL3049378T3 (pl) * | 2013-09-25 | 2019-06-28 | SpecGx LLC | Wytwarzanie radiojodowanego 3-fluoropropylo-nor-beta-CIT |
| GB201321748D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
| WO2023192360A1 (fr) * | 2022-03-31 | 2023-10-05 | Incelldx, Inc. | Méthodes de traitement d'un sujet pour une maladie de lyme post-traitement (ptld) et compositions destinées à être utilisées dans celles-ci |
| WO2023192361A1 (fr) * | 2022-03-31 | 2023-10-05 | Incelldx, Inc. | Procédés de traitement d'un sujet pour la fibromyalgie et compositions destinées à être utilisées dans ceux-ci |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| EP0756596B1 (fr) | 1994-04-19 | 2002-08-21 | Neurosearch A/S | Derives de tropane-2-aldoxime en tant qu'inhibiteurs de recaptage des neurotransmetteurs |
| GB9518953D0 (en) * | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| US6288079B1 (en) | 1996-02-22 | 2001-09-11 | Neurosearch A/S | Tropane-derivatives, their preparation and use |
| WO2000035298A1 (fr) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing-gum contenant des agents medicamenteux actifs |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| PE20001420A1 (es) * | 1998-12-23 | 2000-12-18 | Pfizer | Moduladores de ccr5 |
| SK286129B6 (sk) * | 2000-05-26 | 2008-04-07 | Pfizer Inc. | Tropánové deriváty, ich použitie, spôsob a medziprodukt na ich výrobu, kombinácia a farmaceutická kompozícia s ich obsahom |
| CN1324025C (zh) * | 2002-04-08 | 2007-07-04 | 美国辉瑞有限公司 | 作为ccr5调节剂的托烷衍生物 |
| US6855724B2 (en) * | 2002-04-08 | 2005-02-15 | Agouron Pharmaceuticals, Inc. | Tropane derivatives useful in therapy |
-
2004
- 2004-09-28 DE DE602004010708T patent/DE602004010708T2/de not_active Expired - Lifetime
- 2004-09-28 DK DK04769496T patent/DK1682545T3/da active
- 2004-09-28 WO PCT/IB2004/003153 patent/WO2005033107A1/fr active IP Right Grant
- 2004-09-28 AP AP2006003580A patent/AP2174A/xx active
- 2004-09-28 SI SI200430564T patent/SI1682545T1/sl unknown
- 2004-09-28 ES ES04769496T patent/ES2295924T3/es not_active Expired - Lifetime
- 2004-09-28 EA EA200600480A patent/EA009941B1/ru not_active IP Right Cessation
- 2004-09-28 AU AU2004278158A patent/AU2004278158B2/en not_active Ceased
- 2004-09-28 PL PL04769496T patent/PL1682545T3/pl unknown
- 2004-09-28 OA OA1200600114A patent/OA13266A/en unknown
- 2004-09-28 GE GEAP20049330A patent/GEP20084417B/en unknown
- 2004-09-28 PT PT04769496T patent/PT1682545E/pt unknown
- 2004-09-28 RS YUP-2006/0198A patent/RS20060198A/sr unknown
- 2004-09-28 US US10/953,136 patent/US7309790B2/en not_active Expired - Fee Related
- 2004-09-28 BR BRPI0414862-2A patent/BRPI0414862A/pt not_active IP Right Cessation
- 2004-09-28 JP JP2006530737A patent/JP4874107B2/ja not_active Expired - Fee Related
- 2004-09-28 KR KR1020067006293A patent/KR100777885B1/ko not_active IP Right Cessation
- 2004-09-28 NZ NZ545837A patent/NZ545837A/en not_active IP Right Cessation
- 2004-09-28 AT AT04769496T patent/ATE380813T1/de active
- 2004-09-28 EP EP04769496A patent/EP1682545B1/fr not_active Expired - Lifetime
- 2004-09-28 MX MXPA06003749A patent/MXPA06003749A/es active IP Right Grant
- 2004-09-28 CA CA2540834A patent/CA2540834C/fr not_active Expired - Fee Related
- 2004-09-29 HN HN2004000383A patent/HN2004000383A/es unknown
- 2004-09-29 TW TW093129475A patent/TWI280244B/zh not_active IP Right Cessation
- 2004-10-01 PE PE2004000965A patent/PE20050961A1/es not_active Application Discontinuation
- 2004-10-01 AR ARP040103581A patent/AR045856A1/es not_active Application Discontinuation
- 2004-10-01 MY MYPI20044043A patent/MY137609A/en unknown
- 2004-10-01 PA PA20048614301A patent/PA8614301A1/es unknown
- 2004-10-01 UY UY28546A patent/UY28546A1/es unknown
-
2006
- 2006-03-09 IL IL174208A patent/IL174208A0/en unknown
- 2006-04-03 MA MA28906A patent/MA28080A1/fr unknown
- 2006-04-03 EC EC2006006475A patent/ECSP066475A/es unknown
- 2006-05-03 NO NO20061978A patent/NO20061978L/no not_active Application Discontinuation
-
2007
- 2007-08-27 US US11/845,500 patent/US7790740B2/en not_active Expired - Fee Related
-
2008
- 2008-01-30 HR HR20080052T patent/HRP20080052T3/xx unknown
- 2008-02-14 CY CY20081100178T patent/CY1107281T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA28080A1 (fr) | Derives de tropane a substituant imidazopyridine ayant une activite antagoniste des recepteurs ccr5, pour le traitement de l'infection par le vih et de l'inflammation | |
| Romero et al. | Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. | |
| MA50065A (fr) | Dérivés de composés de spiro[3h-indole-3,2´-pyrrolidine]-2(1h)-one et dérivés utilisés comme inhibiteurs de mdm2-p53 | |
| TNSN04194A1 (fr) | Derives de tropane servant de modulateurs de ccr5 | |
| US9623070B2 (en) | Uses of hypoxia-inducible factor inhibitors | |
| MA28064A1 (fr) | Dérivés de pyrrolo [3,4-c] pyrazole actifs comme inhibiteurs de kinases | |
| MA31867B1 (fr) | Agonistes nouveaux des recepteurs de glucocorticoides | |
| MA34655B1 (fr) | Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse | |
| MA38380A1 (fr) | Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr) | |
| MA31419B1 (fr) | Derives de pyridine | |
| MA27009A1 (fr) | Derives de pyrazole pour le traitement d'une infection par le vih | |
| MA41179A (fr) | Composés inhibiteurs de parg | |
| MA32306B1 (fr) | Derives de quinoleines et de quinoxalines en tant qu'inhibiteurs de proteine tyrosine kinases | |
| EA200701036A1 (ru) | Лактамные соединения и их применение в качестве фармацевтических препаратов | |
| MA28429B1 (fr) | Dérivés de 1H-thiéno [2,3-c] pyrazole utiles comme inhibiteurs de kinases | |
| MA46229A (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 | |
| MA49956B1 (fr) | Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak | |
| PH12022551359A1 (en) | Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases | |
| DE602004020638D1 (de) | Pyrimidin-2,4-dion-derivate als gonadotropin freisetzende hormon-rezeptor-antagonisten | |
| MA38679A1 (fr) | Modulateurs du récepteur de cxcr7 | |
| TW200812589A (en) | Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein, interleukin-6, or interferon-gamma levels | |
| NO20090190L (no) | Modulatorer av kjemokin reseptor aktivitet, krystallinske former og fremgangsmate | |
| MA38694A2 (fr) | Dérivés thérapeutiquement actifs d'estratriène-thiazole à substitution azote en position 17 en tant qu'inhibiteurs de la 17bêta.-hydroxystéroïde déshydrogénase | |
| Lau et al. | Mechanisms of direct relaxant effect of sildenafil, tadalafil and vardenafil on corpus cavernosum | |
| US10906876B2 (en) | Tetrahydroisoquinolines as selective NADPH oxidase 2 inhibitors |